;

Home >> Life Sciences >>

Global Duchenne Muscular Dystrophy Drugs Market Report 2020 - Industry Analysis Size Share Trends Segment and Forecasts to 2025 (Based on 2020 COVID-19 Analysis)

Published: Oct-2020 | Format: PDF | Maia Research | Number of pages: 129 | Code: MRS - 775748

The Duchenne Muscular Dystrophy Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Duchenne Muscular Dystrophy Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Duchenne Muscular Dystrophy Drugs market. The report focuses on well-known providers in the global Duchenne Muscular Dystrophy Drugs industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Duchenne Muscular Dystrophy Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.
In Chapter 2.4, we analyzed industry trends in the context of COVID-19.
In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.
In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.
In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Key players in the global Duchenne Muscular Dystrophy Drugs market covered in Chapter 4:
Sarepta Therapeutics
Catabasis Pharmaceuticals
Akashi Therapeutics
Acceleron Pharma
Asklepios BioPharmaceuticals
Nippon Shinyaku
Nobelpharma
Lexicon Pharmaceuticals
Summit Therapeutics
Taiho Pharmaceutical
Janssen Pharmaceuticals
Italfarmaco
Bristol-Myers Squibb
Pfizer
Marathon Pharmaceuticals
Santhera Pharmaceuticals
BioMarin Pharmaceutical
PTC Therapeutics
Capricor Therapeutics
Eli Lilly

In Chapter 11 and 13.3, on the basis of types, the Duchenne Muscular Dystrophy Drugs market from 2015 to 2026 is primarily split into:
Exondys51
Translarna
Emflaza

In Chapter 12 and 13.4, on the basis of applications, the Duchenne Muscular Dystrophy Drugs market from 2015 to 2026 covers:
Hospitals
Home care settings
Clinics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:
North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 9 and 13)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2026
Table of Content

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Regulatory Scenario by Region/Country
1.4 Market Investment Scenario Strategic
1.5 Market Analysis by Type
1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Type (2020-2026)
1.5.2 Exondys51
1.5.3 Translarna
1.5.4 Emflaza
1.6 Market by Application
1.6.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application (2020-2026)
1.6.2 Hospitals
1.6.3 Home care settings
1.6.4 Clinics
1.7 Duchenne Muscular Dystrophy Drugs Industry Development Trends under COVID-19 Outbreak
1.7.1 Global COVID-19 Status Overview
1.7.2 Influence of COVID-19 Outbreak on Duchenne Muscular Dystrophy Drugs Industry Development

2. Global Market Growth Trends
2.1 Industry Trends
2.1.1 SWOT Analysis
2.1.2 Porter’s Five Forces Analysis
2.2 Potential Market and Growth Potential Analysis
2.3 Industry News and Policies by Regions
2.3.1 Industry News
2.3.2 Industry Policies
2.4 Industry Trends Under COVID-19

3 Value Chain of Duchenne Muscular Dystrophy Drugs Market
3.1 Value Chain Status
3.2 Duchenne Muscular Dystrophy Drugs Manufacturing Cost Structure Analysis
3.2.1 Production Process Analysis
3.2.2 Manufacturing Cost Structure of Duchenne Muscular Dystrophy Drugs
3.2.3 Labor Cost of Duchenne Muscular Dystrophy Drugs
3.2.3.1 Labor Cost of Duchenne Muscular Dystrophy Drugs Under COVID-19
3.3 Sales and Marketing Model Analysis
3.4 Downstream Major Customer Analysis (by Region)
3.5 Value Chain Status Under COVID-19

4 Players Profiles
4.1 Sarepta Therapeutics
4.1.1 Sarepta Therapeutics Basic Information
4.1.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.1.4 Sarepta Therapeutics Business Overview
4.2 Catabasis Pharmaceuticals
4.2.1 Catabasis Pharmaceuticals Basic Information
4.2.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.2.3 Catabasis Pharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.2.4 Catabasis Pharmaceuticals Business Overview
4.3 Akashi Therapeutics
4.3.1 Akashi Therapeutics Basic Information
4.3.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.3.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.3.4 Akashi Therapeutics Business Overview
4.4 Acceleron Pharma
4.4.1 Acceleron Pharma Basic Information
4.4.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.4.3 Acceleron Pharma Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.4.4 Acceleron Pharma Business Overview
4.5 Asklepios BioPharmaceuticals
4.5.1 Asklepios BioPharmaceuticals Basic Information
4.5.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.5.3 Asklepios BioPharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.5.4 Asklepios BioPharmaceuticals Business Overview
4.6 Nippon Shinyaku
4.6.1 Nippon Shinyaku Basic Information
4.6.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.6.3 Nippon Shinyaku Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.6.4 Nippon Shinyaku Business Overview
4.7 Nobelpharma
4.7.1 Nobelpharma Basic Information
4.7.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.7.3 Nobelpharma Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.7.4 Nobelpharma Business Overview
4.8 Lexicon Pharmaceuticals
4.8.1 Lexicon Pharmaceuticals Basic Information
4.8.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.8.3 Lexicon Pharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.8.4 Lexicon Pharmaceuticals Business Overview
4.9 Summit Therapeutics
4.9.1 Summit Therapeutics Basic Information
4.9.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.9.3 Summit Therapeutics Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.9.4 Summit Therapeutics Business Overview
4.10 Taiho Pharmaceutical
4.10.1 Taiho Pharmaceutical Basic Information
4.10.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.10.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.10.4 Taiho Pharmaceutical Business Overview
4.11 Janssen Pharmaceuticals
4.11.1 Janssen Pharmaceuticals Basic Information
4.11.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.11.3 Janssen Pharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.11.4 Janssen Pharmaceuticals Business Overview
4.12 Italfarmaco
4.12.1 Italfarmaco Basic Information
4.12.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.12.3 Italfarmaco Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.12.4 Italfarmaco Business Overview
4.13 Bristol-Myers Squibb
4.13.1 Bristol-Myers Squibb Basic Information
4.13.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.13.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.13.4 Bristol-Myers Squibb Business Overview
4.14 Pfizer
4.14.1 Pfizer Basic Information
4.14.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.14.3 Pfizer Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.14.4 Pfizer Business Overview
4.15 Marathon Pharmaceuticals
4.15.1 Marathon Pharmaceuticals Basic Information
4.15.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.15.3 Marathon Pharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.15.4 Marathon Pharmaceuticals Business Overview
4.16 Santhera Pharmaceuticals
4.16.1 Santhera Pharmaceuticals Basic Information
4.16.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.16.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.16.4 Santhera Pharmaceuticals Business Overview
4.17 BioMarin Pharmaceutical
4.17.1 BioMarin Pharmaceutical Basic Information
4.17.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.17.3 BioMarin Pharmaceutical Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.17.4 BioMarin Pharmaceutical Business Overview
4.18 PTC Therapeutics
4.18.1 PTC Therapeutics Basic Information
4.18.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.18.3 PTC Therapeutics Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.18.4 PTC Therapeutics Business Overview
4.19 Capricor Therapeutics
4.19.1 Capricor Therapeutics Basic Information
4.19.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.19.3 Capricor Therapeutics Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.19.4 Capricor Therapeutics Business Overview
4.20 Eli Lilly
4.20.1 Eli Lilly Basic Information
4.20.2 Duchenne Muscular Dystrophy Drugs Product Profiles, Application and Specification
4.20.3 Eli Lilly Duchenne Muscular Dystrophy Drugs Market Performance (2015-2020)
4.20.4 Eli Lilly Business Overview

5 Global Duchenne Muscular Dystrophy Drugs Market Analysis by Regions
5.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Regions
5.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Regions (2015-2020)
5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions (2015-2020)
5.2 North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
5.3 Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
5.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
5.5 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
5.6 South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)

6 North America Duchenne Muscular Dystrophy Drugs Market Analysis by Countries
6.1 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Countries (2015-2020)
6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2015-2020)
6.1.3 North America Duchenne Muscular Dystrophy Drugs Market Under COVID-19
6.2 United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
6.2.1 United States Duchenne Muscular Dystrophy Drugs Market Under COVID-19
6.3 Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
6.4 Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)

7 Europe Duchenne Muscular Dystrophy Drugs Market Analysis by Countries
7.1 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Countries (2015-2020)
7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries (2015-2020)
7.1.3 Europe Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.2 Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.2.1 Germany Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.3 UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.3.1 UK Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.4 France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.4.1 France Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.5 Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.5.1 Italy Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.6 Spain Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.6.1 Spain Duchenne Muscular Dystrophy Drugs Market Under COVID-19
7.7 Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
7.7.1 Russia Duchenne Muscular Dystrophy Drugs Market Under COVID-19

8 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Analysis by Countries
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
8.1.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries (2015-2020)
8.1.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries (2015-2020)
8.1.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Under COVID-19
8.2 China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.2.1 China Duchenne Muscular Dystrophy Drugs Market Under COVID-19
8.3 Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.3.1 Japan Duchenne Muscular Dystrophy Drugs Market Under COVID-19
8.4 South Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.4.1 South Korea Duchenne Muscular Dystrophy Drugs Market Under COVID-19
8.5 Australia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.6 India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.6.1 India Duchenne Muscular Dystrophy Drugs Market Under COVID-19
8.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
8.7.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Under COVID-19

9 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Analysis by Countries
9.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries (2015-2020)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries (2015-2020)
9.1.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Under COVID-19
9.2 Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
9.3 UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
9.5 Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
9.6 South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)

10 South America Duchenne Muscular Dystrophy Drugs Market Analysis by Countries
10.1 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
10.1.1 South America Duchenne Muscular Dystrophy Drugs Sales by Countries (2015-2020)
10.1.2 South America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2015-2020)
10.1.3 South America Duchenne Muscular Dystrophy Drugs Market Under COVID-19
10.2 Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
10.2.1 Brazil Duchenne Muscular Dystrophy Drugs Market Under COVID-19
10.3 Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
10.4 Columbia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)
10.5 Chile Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2015-2020)

11 Global Duchenne Muscular Dystrophy Drugs Market Segment by Types
11.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Types (2015-2020)
11.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Types (2015-2020)
11.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Types (2015-2020)
11.2 Exondys51 Sales and Price (2015-2020)
11.3 Translarna Sales and Price (2015-2020)
11.4 Emflaza Sales and Price (2015-2020)

12 Global Duchenne Muscular Dystrophy Drugs Market Segment by Applications
12.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Applications (2015-2020)
12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Applications (2015-2020)
12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Applications (2015-2020)
12.2 Hospitals Sales, Revenue and Growth Rate (2015-2020)
12.3 Home care settings Sales, Revenue and Growth Rate (2015-2020)
12.4 Clinics Sales, Revenue and Growth Rate (2015-2020)

13 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2020-2026)
13.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Growth Rate (2020-2026)
13.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2020-2026)
13.2.1 North America Duchenne Muscular Dystrophy Drugs Market Forecast (2020-2026)
13.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2020-2026)
13.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Forecast (2020-2026)
13.2.4 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2020-2026)
13.2.5 South America Duchenne Muscular Dystrophy Drugs Market Forecast (2020-2026)
13.3 Duchenne Muscular Dystrophy Drugs Market Forecast by Types (2020-2026)
13.4 Duchenne Muscular Dystrophy Drugs Market Forecast by Applications (2020-2026)
13.5 Duchenne Muscular Dystrophy Drugs Market Forecast Under COVID-19

14 Appendix
14.1 Methodology
14.2 Research Data Source


                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3400 View Pricing